Dyne Therapeutics, Inc.
DYN
Updated: 24/09/2026, 20:50:15
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
No summaries found.
- Share price
- $16.52
- Market cap
- $3.08B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- John G. Cox
- Employees
- 289
- IPO date
- 17/09/2020
- Beta
- 1.078
- Last dividend
- $0.00
- Day range
- $15.88 – $16.65
- 52-week range
- $11.92 – $27.31
- 1-day performance
- 1.81%
- 1-year performance
- 38.62%
- Current drawdown (1Y)
- -39.48%
- CIK
- 0001818794
- CUSIP
- 26818M108
- ISIN
- US26818M1080
- Created
- 07/12/2025, 03:41:43
- Last update
- 24/09/2026, 20:50:15
Track Dyne Therapeutics, Inc. with an AI analyst
See which prediction-market events move DYN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
GlobeNewsWire • STOCK • 03/06/2026, 09:30:00
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
Zacks Investment Research • STOCK • 27/05/2026, 13:21:05
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
GlobeNewsWire • STOCK • 26/05/2026, 09:30:00
Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission
Seeking Alpha • STOCK • 21/05/2026, 16:37:15
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
Zacks Investment Research • STOCK • 21/05/2026, 14:36:13
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
GlobeNewsWire • STOCK • 20/05/2026, 09:46:00
Dyne Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire • STOCK • 13/05/2026, 09:30:00
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research • STOCK • 11/05/2026, 15:01:15
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewsWire • STOCK • 11/05/2026, 09:30:00
Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript
Seeking Alpha • STOCK • 09/03/2026, 16:27:58
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case
Seeking Alpha • STOCK • 09/03/2026, 14:30:15
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
GlobeNewsWire • STOCK • 08/03/2026, 19:01:00